Copyright
©The Author(s) 2020.
World J Gastroenterol. Sep 7, 2020; 26(33): 4960-4971
Published online Sep 7, 2020. doi: 10.3748/wjg.v26.i33.4960
Published online Sep 7, 2020. doi: 10.3748/wjg.v26.i33.4960
Figure 4 Time-course changes from baseline to 12 mo of denosumab treatment.
A: In the levels of serum tartrate-resistant acid phosphatase 5b; B: Serum procollagen type N-terminal propeptide; C: Serum calcium; and D: Plasma pentosidine. aP < 0.001 vs baseline.
- Citation: Saeki C, Saito M, Oikawa T, Nakano M, Torisu Y, Saruta M, Tsubota A. Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol 2020; 26(33): 4960-4971
- URL: https://www.wjgnet.com/1007-9327/full/v26/i33/4960.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i33.4960